Sevelamer carbonate 800 mg tablet
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Sevelamer Carbonate 800 mg Tablet: Efficacy, Safety, and Comparative Studies
Introduction to Sevelamer Carbonate
Sevelamer carbonate is a non-calcium phosphate binder used primarily to manage hyperphosphatemia in patients with chronic kidney disease (CKD). It is available in various forms, including 800 mg tablets, and is often compared with other phosphate binders like lanthanum carbonate and calcium-based binders.
Efficacy in Phosphate Binding
Comparison with Lanthanum Carbonate
A study comparing the phosphate absorption of lanthanum carbonate and sevelamer carbonate in healthy volunteers found that lanthanum carbonate was more effective in reducing phosphate absorption. Specifically, lanthanum carbonate decreased net phosphate absorption by 45%, while sevelamer carbonate achieved a 21% reduction. This indicates that while sevelamer carbonate is effective, lanthanum carbonate may offer superior phosphate binding per tablet.
Dose-Titration and Serum Phosphorus Levels
In a randomized, double-blind, dose-titration study involving Chinese hemodialysis patients, sevelamer carbonate significantly reduced serum phosphorus levels compared to placebo. The study demonstrated a mean reduction of -0.69 mmol/L in serum phosphorus with sevelamer carbonate, highlighting its efficacy in managing hyperphosphatemia in CKD patients.
Safety and Tolerability
Gastrointestinal Complications
Sevelamer carbonate has been compared with sevelamer hydrochloride in terms of gastrointestinal side effects. A study found no significant difference in gastrointestinal complications between the two forms, suggesting that both are similarly tolerated by patients. However, another study noted that sevelamer carbonate powder, when administered once daily, resulted in a higher incidence of upper gastrointestinal events like nausea and vomiting compared to thrice-daily sevelamer hydrochloride tablets.
Impact on Serum Calcium and Bicarbonate Levels
Sevelamer carbonate has been shown to have a beneficial effect on serum bicarbonate levels, which can help prevent metabolic acidosis in hemodialysis patients. In contrast, sevelamer hydrochloride did not show a significant change in bicarbonate levels. This makes sevelamer carbonate a preferable option for patients at risk of acidosis.
Comparative Studies with Other Phosphate Binders
Sevelamer vs. Calcium Carbonate
A long-term study comparing sevelamer with calcium carbonate in incident hemodialysis patients found that sevelamer was associated with lower cardiovascular mortality due to cardiac arrhythmias. This suggests that sevelamer may offer cardiovascular benefits over calcium-based binders, potentially due to better phosphate control and reduced calcium load.
Sevelamer vs. Sucroferric Oxyhydroxide
In a 12-week study comparing sevelamer carbonate with sucroferric oxyhydroxide (SFOH), both treatments effectively reduced serum phosphorus levels. However, SFOH achieved target phosphorus levels more quickly and with a lower pill burden, making it a potentially more convenient option for patients.
Conclusion
Sevelamer carbonate 800 mg tablets are effective in managing hyperphosphatemia in CKD patients, with a favorable safety profile. While it may not be as potent as lanthanum carbonate in phosphate binding, it offers significant benefits in terms of serum bicarbonate levels and cardiovascular outcomes compared to calcium-based binders. Further studies are warranted to explore optimal dosing strategies and long-term outcomes in diverse patient populations.
Sources and full results
Most relevant research papers on this topic